Drug resistance and extended-spectrum β-lactamase (ESBLs) - producing Enterobacteriaceae, Acinetobacter and Pseudomonas species from the views of one-health approach in Ethiopia: a systematic review and meta-analysis.

Mengistu Abayneh, Ahmed Zeynudin, Rahel Tamrat, Mulualem Tadesse, Abraham Tamirat
Author Information
  1. Mengistu Abayneh: College of Medical and Health Science, Department of Medical Laboratory Sciences, Mizan-Tepi University, PO Box 260, Mizan-Aman, Ethiopia. menge.abay@gmail.com. ORCID
  2. Ahmed Zeynudin: School of Medical Laboratory Sciences, Faculty of Health Sciences, Institute of Health, Jimma University, Jimma, Ethiopia.
  3. Rahel Tamrat: School of Medical Laboratory Sciences, Faculty of Health Sciences, Institute of Health, Jimma University, Jimma, Ethiopia.
  4. Mulualem Tadesse: School of Medical Laboratory Sciences, Faculty of Health Sciences, Institute of Health, Jimma University, Jimma, Ethiopia.
  5. Abraham Tamirat: Faculity of Public Health, Department of Health, Behavior and Society, Jimma University, Jimma, Ethiopia.

Abstract

BACKGROUND: Although antimicrobial resistance (AMR) bacteria present a significant and ongoing public health challenge, its magnitude remains poorly understood, especially in many parts of the developing countries. Hence, this review was conducted to describe the current pooled prevalence of drug resistance, multidrug- resistance (MDR), and Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, Acinetobacter, and Pseudomonas species in humans, the environment, and animals or food of animal origin in Ethiopia.
METHODS: PubMed, Google Scholar, and other sources were searched for relevant articles as per the preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines. A critical appraisal for screening, eligibility, and inclusion in the meta-analysis was made based on the Joanna Briggs Institute's (JBI) essential appraisal tools. The meta-analysis was done on Statistical Software Package (STATA) version 17.0.
RESULTS: A total of 33 research articles were included in this systematic review and meta-analysis. Escherichia coli, Klebsiella species, Acinetobacter, and Pseudomonas species were the most frequently reported bacteria from two or more sources. More than 50% of Klebsiella species and 25% to 89% of Escherichia coli from two or more sources were resistant to all analysed antibiotics, except carbapenems. Fifty-five percent (55%) to 84% of Acinetobacter species and 33% to 79% of Pseudomonas species from human and environmental sources were resistant to all analyzed antibiotics. Carbapenem resistance was common in Acinetobacter and Pseudomonas species (38% to 64%) but uncommon in Enterobacteriaceae (19% to 44%). Acinetobacter species (92%), Klebsiella species (86%), and Pseudomonas species (79%) from human sources, and Proteus species (92%), and Acinetobacter species (83%), from environmental sources, were the common multidrug-resistant isolates. About 45% to 67% of E. coli, Klebsiella, Acinetobacter, and Pseudomonas species from human and environmental sources were ESBL producers.
CONCLUSION: Our review report concluded that there was a significant pooled prevalence of drug resistance, MDR, and ESBL-producing Enterobacteriaceae, Acinetobacter, and Pseudomonas species from two or more sources. Hence, our finding underlines the need for the implementation of integrated intervention approaches to address the gaps in reducing the emergence and spread of antibiotic- resistant bacteria.

Keywords

References

  1. Int J Environ Res Public Health. 2018 Jun 17;15(6): [PMID: 29914203]
  2. Microb Drug Resist. 2016 Jul;22(5):412-31 [PMID: 26866778]
  3. Infect Drug Resist. 2020 Dec 14;13:4439-4448 [PMID: 33364791]
  4. Infect Drug Resist. 2022 Mar 08;15:895-911 [PMID: 35299856]
  5. BMC Res Notes. 2017 Jul 6;10(1):254 [PMID: 28683780]
  6. Int J Microbiol. 2017;2017:8953829 [PMID: 28386280]
  7. BMC Public Health. 2019 Aug 19;19(1):1135 [PMID: 31426792]
  8. Bull World Health Organ. 2019 Jul 01;97(7):486-501B [PMID: 31258218]
  9. Health Secur. 2018 Fall;16(S1):S30-S36 [PMID: 30480505]
  10. Biomed Res Int. 2016;2016:4290506 [PMID: 28074185]
  11. Infect Dis (Auckl). 2019 Nov 05;12:1178633719884951 [PMID: 31723320]
  12. PLoS One. 2021 Aug 3;16(8):e0255410 [PMID: 34343185]
  13. Res Rep Trop Med. 2021 May 04;12:39-49 [PMID: 33976582]
  14. Environ Health Perspect. 2021 Feb;129(2):27007 [PMID: 33617318]
  15. Risk Manag Healthc Policy. 2021 Jan 26;14:283-291 [PMID: 33531847]
  16. BMJ. 2021 Mar 29;372:n71 [PMID: 33782057]
  17. Lancet. 2022 Feb 12;399(10325):629-655 [PMID: 35065702]
  18. Pharmacotherapy. 2015 Oct;35(10):949-62 [PMID: 26497481]
  19. Int J Evid Based Healthc. 2015 Sep;13(3):132-40 [PMID: 26360830]
  20. Ann Clin Microbiol Antimicrob. 2021 Mar 11;20(1):16 [PMID: 33706775]
  21. Int J Microbiol. 2019 Aug 01;2019:2489063 [PMID: 31467550]
  22. BMC Res Notes. 2018 Jul 31;11(1):524 [PMID: 30064483]
  23. Gastrointest Endosc Clin N Am. 2020 Oct;30(4):619-635 [PMID: 32891221]
  24. Infect Drug Resist. 2022 Mar 29;15:1367-1382 [PMID: 35378892]
  25. PLoS One. 2022 Jan 14;17(1):e0262308 [PMID: 35030183]
  26. Microbiol Spectr. 2018 Mar;6(2): [PMID: 29600770]
  27. Psychol Methods. 2006 Jun;11(2):193-206 [PMID: 16784338]
  28. PLoS One. 2021 Dec 2;16(12):e0256556 [PMID: 34855767]
  29. PLoS One. 2021 Nov 15;16(11):e0257272 [PMID: 34780494]
  30. Microb Drug Resist. 2018 Jun;24(5):648-665 [PMID: 29683779]
  31. Antimicrob Resist Infect Control. 2022 Jan 15;11(1):8 [PMID: 35033191]
  32. One Health. 2022 Apr 20;14:100390 [PMID: 35686143]
  33. Afr J Lab Med. 2016 Sep 15;5(1):432 [PMID: 28879114]
  34. Vet Sci. 2022 Sep 05;9(9): [PMID: 36136696]
  35. Lancet. 2016 Jan 9;387(10014):176-87 [PMID: 26603922]
  36. BMC Res Notes. 2019 Sep 23;12(1):621 [PMID: 31547851]
  37. J Mol Evol. 2020 Jan;88(1):26-40 [PMID: 31659373]
  38. Biomed Res Int. 2022 Jun 2;2022:7272024 [PMID: 38525432]
  39. Antimicrob Resist Infect Control. 2017 May 15;6:47 [PMID: 28515903]
  40. Int J Microbiol. 2020 Jan 18;2020:1910630 [PMID: 32047517]
  41. BMJ Open. 2022 Jun 9;12(6):e051022 [PMID: 35680276]
  42. BMC Infect Dis. 2020 Jan 30;20(1):92 [PMID: 32000693]
  43. BMC Res Notes. 2014 Apr 05;7:215 [PMID: 24708553]
  44. J Glob Antimicrob Resist. 2022 Dec;31:212-215 [PMID: 36202201]
  45. Infect Drug Resist. 2020 Dec 17;13:4509-4517 [PMID: 33364798]
  46. Afr J Lab Med. 2018 Dec 06;7(2):796 [PMID: 30568902]
  47. Infect Drug Resist. 2021 Jun 02;14:2051-2058 [PMID: 34103951]
  48. Antimicrob Agents Chemother. 2006 Aug;50(8):2695-9 [PMID: 16870760]
  49. One Health Outlook. 2022 Apr 22;4(1):8 [PMID: 35449083]
  50. PLoS Med. 2016 Nov 29;13(11):e1002184 [PMID: 27898664]
  51. BMC Microbiol. 2021 Nov 8;21(1):309 [PMID: 34749674]
  52. PLoS One. 2022 Jul 7;17(7):e0271022 [PMID: 35797393]
  53. Lancet Infect Dis. 2018 Aug;18(8):e248-e258 [PMID: 29519767]
  54. J Glob Antimicrob Resist. 2021 Sep;26:133-139 [PMID: 34129993]
  55. Antimicrob Resist Infect Control. 2018 Nov 19;7:138 [PMID: 30479751]
  56. Environ Sci Technol. 2017 Jun 6;51(11):5863-5864 [PMID: 28489349]
  57. Antimicrob Resist Infect Control. 2020 Jan 13;9(1):14 [PMID: 31956403]
  58. Antimicrob Resist Infect Control. 2017 Oct 23;6:106 [PMID: 29075483]
  59. Int J Bacteriol. 2016;2016:3714785 [PMID: 27660816]
  60. Wellcome Open Res. 2017 Sep 26;2:91 [PMID: 29181453]

Word Cloud

Created with Highcharts 10.0.0speciesAcinetobacterPseudomonassourcesresistancemeta-analysisreviewEnterobacteriaceaeKlebsiellabacteriaMDRsystematiccolitworesistanthumanenvironmentalsignificantHencepooledprevalencedrugβ-lactamaseESBLEthiopiaarticlesappraisalEscherichiaantibiotics79%common92%DrugBACKGROUND:AlthoughantimicrobialAMRpresentongoingpublichealthchallengemagnituderemainspoorlyunderstoodespeciallymanypartsdevelopingcountriesconducteddescribecurrentmultidrug-Extended-spectrum-producinghumansenvironmentanimalsfoodanimaloriginMETHODS:PubMedGoogleScholarsearchedrelevantperpreferredreportingitemsreviewsPRISMAguidelinescriticalscreeningeligibilityinclusionmadebasedJoannaBriggsInstitute'sJBIessentialtoolsdoneStatisticalSoftwarePackageSTATAversion170RESULTS:total33researchincludedfrequentlyreported50%25%89%analysedexceptcarbapenemsFifty-fivepercent55%84%33%analyzedCarbapenem38%64%uncommon19%44%86%Proteus83%multidrug-resistantisolates45%67%EproducersCONCLUSION:reportconcludedESBL-producingfindingunderlinesneedimplementationintegratedinterventionapproachesaddressgapsreducingemergencespreadantibiotic-extended-spectrumESBLs-producingviewsone-healthapproachEthiopia:resistance/ESBL-productionGram-negatives

Similar Articles

Cited By